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Abstract
A multicenter, retrospective, observational study of 4-factor prothrombin complex concentrate (PCC) and/or fresh frozen
plasma (FFP) use within routine clinical care unrelated to vitamin K antagonists was conducted. The PCC was administered
preprocedure for correction of coagulopathy (prophylactic cohort) and treatment of bleeding postsurgery (treatment cohort). Of
the 445 patients included, 40 were in the prophylactic cohort (PCC alone [n¼ 16], PCC and FFP [n¼ 5], FFP alone [n¼ 19]) and
405 were in the treatment cohort (PCC alone [n¼ 228], PCC and FFP [n¼ 123], FFP alone [n¼ 54]). Cardiovascular surgery was
the most common setting. PCC doses ranged between 500 and 5000 IU. Effectiveness (assessed retrospectively) was reported as
effective in 93.0% in the PCC-only group (95% confidence interval, 89.1% to 95.9%), 78.9% (70.8% to 85.6%) with PCC and FFP,
and 86.3% (76.2% to 93.2%) with FFP alone. In the treatment cohort, international normalized ratio was significantly reduced in all
3 groups. In patients who received PCC, the rate of thromboembolic events (1.9%) was below rates in the literature for similar
procedures. PCCs offer a potential alternative to FFP in the management of perioperative bleeding unrelated to oral anticoagulant
therapy.
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Background
Acquired coagulopathy is the most common indication for
transfusing fresh frozen plasma (FFP).1 The aim of the treat-
ment is to prevent procedure-related bleeding or manage acute
bleeding by restoring deficient coagulation factors. A pro-
longed prothrombin time (PT) or a high international normal-
ized ratio (INR) is often used as a trigger for transfusion,2
although neither PT nor INR is validated to predict risk of
bleeding.1,3 Studies have shown that increments in coagulation
factor levels following standard doses of FFP do not reliably
correct coagulopathy, whereas prothrombin complex concentrates
(PCCs; 20-50 IU/kg) or higher doses of FFP (*30 mL/kg) can
increase coagulation factor concentration to levels considered
to be adequate for hemostasis.4,5
PCCs are well established for emergency reversal of oral
anticoagulation with vitamin K antagonists.6 Beriplex P/N
(CSL Behring, Marburg, Germany) is a 4-factor PCC contain-
ing coagulation factors II, VII, IX, and X along with proteins C,
S, and Z. It is licensed in the United Kingdom and Europe for
treatment and perioperative prophylaxis of bleeding related to
acquired deficiencies in vitamin K-dependent coagulation fac-
tors, and for treatment and perioperative prophylaxis of bleed-
ing in congenital deficiency of any of the vitamin K-dependent
coagulation factors.7 In other countries such as the United
States, PCCs are not licensed for the treatment of acquired
coagulopathy. However, there has been increasing interest in
using PCCs to treat bleeding beyond the setting of anticoagula-
tion reversal, as they enable rapid administration of adequate
doses of coagulation factors with small administration
volumes. Unlike FFP, PCCs do not need to be thawed before
administration, and they can be reconstituted rapidly.8 Further-
more, the manufacturing process for coagulation factor concen-
trates includes purification and viral inactivation, minimizing
potential risks such as pathogen transmission, and transfusion-
related acute lung injury.9-12
Limited retrospective studies have shown the effectiveness
of PCCs in surgical bleeding.13-17 Recent European anesthe-
siology guidelines state that goal-directed therapy with coagu-
lation factor concentrates (fibrinogen and/or PCC) may reduce
transfusion-associated costs in trauma, cardiac surgery, and
liver transplantation.18 American anesthesiology guidelines
suggest PCCs for bleeding in the presence of elevated INR,19
and European trauma guidelines suggest administration of PCC
to bleeding patients with thromboelastometric evidence of
delayed coagulation initiation.20 However, because the pub-
lished literature on this is limited, the primary basis for these
recommendations is expert opinion. Relevant guidelines from
the United Kingdom do not include recommendations for using
PCC except for anticoagulation reversal.21
A multicenter, retrospective, observational study of 4-factor
PCC use within routine clinical care in the United Kingdom
was undertaken (“ProBe” study: Prothrombin complex con-
centrate and Beriplex). The primary objective was to evaluate
the clinical effectiveness of PCC for prophylaxis or treatment
of perioperative bleeding in patients not taking oral
anticoagulant therapy (ie, vitamin K antagonists). Secondary
objectives were to assess safety and tolerability of PCC by
frequency of adverse drug reactions (ADRs); to evaluate the
dose–response relationship with PCC; and to compare char-
acteristics of patients treated with PCC with those of FFP-
treated patients.
Methods
Study Design
This was a multicenter, retrospective, noninterventional, obser-
vational study of 4-factor PCC, conducted in 9 centers in the
United Kingdom over a period of 20 months (May 2010-January
2012). The study was carried out in accordance with the Inter-
national Conference on Harmonization Good Clinical Practice
guidelines and the Declaration of Helsinki and registered at
www.clinicaltrials.gov (NCT01053169). The study was
approved by an independent ethics committee (National Hospi-
tal for Neurology and Neurosurgery and Institute of Neurology
Research Ethics Committee—09/H0716/74), and informed con-
sent was waived for the data collection. The waiver was pro-
vided because PCC was often a small component of patients’
overall treatment (patients were unlikely to be familiar with
every intervention), and to ensure data validity, there was a need
to include all potentially eligible patients (not all patients were
available for discussion and consent postintervention).22 The
study was funded and sponsored by CSL Behring.
Standard practices in the participating centers were followed
for the administration of PCC and FFP and sampling for assess-
ment of hemostasis. Based on the reason for treatment with PCC
and/or FFP, 2 patient cohorts were defined: a prophylactic cohort
and a treatment cohort. The prophylactic cohort included
patients with acquired coagulopathy presenting with prolonged
PT or INR due to a medical condition who required surgical or
diagnostic intervention and received PCC and/or FFP to prevent
bleeding. Patients in the treatment cohort received PCC and/or
FFP to stop or reduce acute perioperative bleeding.
Patient Cohort and Treatment Details
Patients who received Beriplex P/N and/or FFP for prevention
or treatment of bleeding were potentially eligible for inclusion.
The decision to use PCC was dictated by individual clinicians
based on institutional practice. Other inclusion criteria for both
cohorts were age"16 years, administration of FFP or PCC, and
availability of the following information: reason for treatment
with PCC and/or FFP, administered dose, treatment outcome,
blood product transfusion, and concurrent hemostatic therapy
given. Additional inclusion criteria for the prophylactic cohort
were coagulopathy, defined as INR >1.4 or PT "3 seconds
above the upper limit of the reporting laboratory’s normal
range and any planned major or minimally invasive procedure.
The exclusion criteria for both cohorts were treatment with
PCC other than Beriplex P/N and reversal of anticoagulation
secondary to oral vitamin K antagonist therapy.
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Centers were encouraged to include all potentially eligible
patients who received PCCs between May 2010 and January
2012. A small group of patients who received FFP alone for the
same reasons was also included to observe standard practice,
and recruitment to this arm was by competitive enrollment until
target numbers were reached.
For each study participant, the following data were
entered into an electronic database: patient characteristics,
relevant medical history, vital signs, diagnosis, intervention
undertaken, cause of coagulopathy, source of bleeding, and
reason(s) for administering PCC or FFP (ie, all clinical
triggers for treatment). The clinical triggers for administer-
ing PCCs included blood loss (eg, >20%), ongoing micro-
vascular (nonsurgical) bleeding as assessed by the surgeon,
abnormal coagulation parameters (eg, INR and PT),
abnormalities on point-of-care testing; clinicians were asked
to indicate all relevant indications for each patient. In
addition, details of treatment with other blood products or
hemostatic therapy including red blood cells, platelets, cryo-
precipitate, fibrinogen concentrate, vitamin K, desmopres-
sin, tranexamic acid, and recombinant activated factor VII
were collected. When available, INR and other laboratory
parameters (eg, activated partial thromboplastin time, hemo-
globin, platelet count, and fibrinogen concentration) were
documented at 3 time points: before treatment and at about
3 and 24 hours posttreatment. Both surgical and microvas-
cular bleeding were included.
The clinical effect of PCC/FFP was assessed retrospec-
tively by the investigators, based on patient notes at each
center. Perceived effectiveness in preventing or stopping
bleeding was rated as “very good” (prompt cessation of
bleeding and/or rapid fall in INR [<1.6]; hemostasis during
surgery not significantly different from normal),
“satisfactory” (delayed cessation of bleeding and/or delayed
fall in INR [1-2 hours]; mildly abnormal hemostasis during
surgery in terms of quantity and/or quality [slight oozing]),
“questionable,” or “doubtful” (cessation of bleeding and fall
in INR after >2 hours; moderately abnormal hemostasis
during surgery [controllable bleeding]), “none” (lack of
effect on bleeding and insufficient fall in INR; severely
abnormal hemostasis during surgery [severe hemorrhage,
difficult to control]), or “no judgment possible.” The defi-
nitions for each category were subjective and based on those
utilized in prior clinical trials of PCC and surgery in
patients with hemophilia.23,24 One overall rating was pro-
vided for each patient regardless of the number of doses of
PCC and/or FFP administered. Adequate effectiveness was
defined as very good or satisfactory effectiveness in pre-
venting/stopping bleeding. The effect of PCCs on INR was
also assessed.
The ADRs that were judged by the investigator to be at least
possibly related to PCC (including thromboembolic events),
and all deaths among recipients of PCC (irrespective of cause),
were collected during a 24-hour observation period following
the last administration of PCC. Neither ADRs nor deaths were
collected in relation to FFP.
Statistical Analysis
A sample size calculation was not performed because of the
observational nature of the study and the lack of previous data.
A minimum total of 200 patients was planned to obtain suffi-
cient evaluable patients treated with PCC. For the group treated
with FFP alone, a maximum of 50 patients was allowed to be
documented. After database lock, it was decided that a regroup-
ing of the patients would be useful to analyze the data, with 3
groups described within each cohort: PCC alone, FFP alone,
and PCC and FFP. No statistical comparisons were made
between these groups.
Clinical effectiveness was assessed by descriptive statistics
in keeping with the primary and secondary objectives. The
treatment was considered effective when a rating of very good
or satisfactory was provided by the investigator. Results are
presented as mean and standard deviation for parameters fol-
lowing the normal distribution and median and interquartile
range (IQR) for nonnormal distributions.
The relationship between total PCC dose and clinical effec-
tiveness was analyzed by categorizing patients into dose groups
(for patients with more than 1 administration of PCC, the total
dose was calculated from all administrations). Three dose cate-
gories were defined (<10 IU/kg, 10-19.9 IU/kg, and"20 IU/kg,
corresponding approximately to doses of 500, 1000, and
"1500 IU, respectively). Responses of “no judgment possible”
were considered to be missing data, and these patients were
excluded. Fisher’s exact test was used to examine whether
there was an association between dose and a number of cate-
gorical variables, including the percentage of patients in whom
PCC was deemed to have adequate effectiveness. The Kruskal-
Wallis test was used to compare continuous variables between
the 3 dose categories. The criterion for statistical significance
was set as P < .05. As concurrent transfusion of other hemo-
static products is a major confounder, details of blood product
usage stratified by PCC dose are provided.
Results
Patient Characteristics
A total of 445 patients were recruited: 40 in the prophylactic
cohort and 405 in the treatment cohort. In total, 372 patients
received PCC with or without FFP and 73 received FFP alone.
Patient characteristics (Table 1) were generally consistent
across patients receiving FFP alone, PCC alone, or PCC and
FFP (treatment and prophylactic cohorts combined). However,
platelet count and hemoglobin were numerically lower among
patients receiving PCC and FFP versus those receiving either
treatment alone. No ADR data were available for 4 recipients
of PCC who were consequently excluded from the safety pop-
ulation (n ¼ 368).
In 93% of prophylactic cohort (37/40 patients), an abnormal
coagulation test result prior to a surgical procedure was the
indication for treatment. The remaining 3 (8%) patients had a
history of excessive bleeding. Reasons for PCC administration
in the treatment cohort, in addition to bleeding, were
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documented as follows: 43% (175/405 patients) had abnormal
point-of-care test results and abnormal laboratory test results
were seen in 27% (109/405 patients). Microvascular bleeding
was noted in 23% of the treatment cohort (93/405 patients), and
no coagulation test result was available in 41% (166/405
patients). These patients were treated for diffuse oozing and
clinically diagnosed bleeding. Details of the patients’ interven-
tions and/or procedures are shown in Table 2. Cardiovascular
surgery (eg, coronary artery bypass graft [CABG]) was the
most common setting in the treatment cohort, and this is a
reflection of the centers participating in the study.
Treatment Details Including Allogeneic Blood Products
The median total dose of PCC in the prophylactic cohort was
1500 IU (22.5 IU/kg; 60 mL; IQR, 1250-2125 IU), and in the
treatment cohort, it was 1000 IU (11.5 IU/kg; 40 mL; IQR,
500-1000 IU). Most patients received only 1 dose of PCC:
85.7% (18/21 patients) in the prophylactic cohort and 87.2%
(306/351 patients) in the treatment cohort. In the prophylactic
cohort, the remaining 3 patients received 2 doses, while in the
treatment cohort 10.5% (37/351 patients) received 2 doses and
2.3% (8/351 patients) received 3 doses. Single doses ranged
between 500 and 5000 IU.
The median total dose of FFP among recipients of FFP-only
in the prophylactic cohort was 1000 mL (14.5 mL/kg; IQR,
1000-1000 mL), and in the treatment cohort, it was 825 mL
(11.0 mL/kg; IQR, 550-1100 mL). Similar to PCC, 94.7%
(18/19 patients) of the prophylactic cohort treated with FFP
alone received only 1 dose, compared to 87.0% (47/54 patients)
in the treatment cohort. In the prophylactic cohort, 1 (5.3%)
patient received 2 doses, while in the treatment cohort 3 (5.6%)
patients received 2 doses, 2 (3.7%) patients received 3 doses,
and 2 (3.7%) patients received 4 doses.
Platelets were the most commonly administered blood prod-
uct after PCC/FFP, with 35.0% of patients in the prophylactic
cohort and 60.0% of those in the treatment cohort receiving this
treatment. The second and third most commonly administered
products were red blood cells (prophylactic cohort, 37.5%;
treatment cohort, 46.4%) and cryoprecipitate (2.5%; 25.2%).
Tranexamic acid was administered to 10.0% of patients in the
prophylactic cohort and 1.5% of those in the treatment cohort.
Recombinant activated factor VII was administered to 5.0% of
patients in the prophylactic cohort and 2.2% of those in the
treatment cohort, and fibrinogen concentrate was given to
10.0% and 1.0%, respectively.
Response to Treatment: Clinical Effectiveness,
Transfusion, and Laboratory Parameters
Across both cohorts (prophylactic and treatment), treatment
was reported to be effective in 93.0% of patients receiving PCC
alone (95% confidence interval [CI]: 89.1% to 95.9%), in
78.9% (70.8% to 85.6%) of those receiving PCC and FFP, and
in 86.3% (76.2% to 93.2%) of patients receiving FFP alone.
When analyzed separately, in the prophylactic cohort, treat-
ment was reported to be effective in 87.5% of patients who
received PCC alone, 80.0% of patients who received PCC and
FFP, and 78.9% of recipients of FFP alone (Figure 1). Corre-
sponding percentages in the treatment cohort were 93.4%,
78.9%, and 88.9%, respectively.
Statistical analysis of the dose–response relationship was
restricted to the treatment cohort, as there were too few patients
in the prophylactic cohort for meaningful comparisons. No
significant association was noted between dose and effective-
ness among patients receiving PCC alone, while the incidence
of adequate effectiveness decreased significantly with
Table 1. Baseline Characteristics of Patients.
By Cohort By Type of Treatment Administered
Prophylactic
Cohort, n ¼ 40
Treatment
Cohort, n ¼ 405
PCC
Alone, n ¼ 244
PCC and
FFP, n ¼ 128
FFP Alone,
n ¼ 73
All Patients,
N ¼ 445
Gender, n (%), N ¼ 445
Male 20 (50.0) 259 (64.0) 149 (61.1) 84 (65.6) 46 (63.0) 279 (62.7)
Female 20 (50.0) 146 (36.0) 95 (38.9) 44 (34.4) 27 (37.0) 166 (37.3)
Age, years, N ¼ 445
Mean (SD) 59.0 (18.7) 69.6 (13.3) 69.4 (13.9) 66.9 (15.8) 69.1 (12.2) 68.6 (14.2)
Height, cm, n ¼ 418
Mean (SD) 166.7 (7.8) 168.9 (10.9) 168.2 (11.4) 169.7 (10.3) 168.6 (9.0) 168.7 (10.7)
Weight, kg, N ¼ 445
Mean (SD) 73.1 (18.8) 77.1 (15.6) 75.9 (16.0) 78.8 (16.8) 75.8 (14.3) 76.7 (16.0)
Body mass index, kg/m2, n ¼ 418
Mean (SD) 26.5 (7.0) 27.0 (4.8) 26.8 (5.0) 27.6 (5.2) 26.8 (4.5) 27.0 (5.0)
Hemoglobin, g/dLa, n ¼ 307
Mean (SD) 9.7 (2.5) 9.4 (1.9) 9.6 (1.8) 9.1 (1.9) 9.9 (2.7) 9.5 (2.0)
Platelet count, #109/La, n ¼ 248
Median (IQR) 176 (65, 267) 130 (98, 164) 136 (102, 185) 115 (86, 161) 134 (106, 198) 130 (96, 171)
Abbreviations: FFP, fresh frozen plasma; IQR, interquartile range; PCC, prothrombin complex concentrate; SD, standard deviation
aMeasurement taken within 3 hours before study medication.
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increasing PCC dose among patients receiving PCC and FFP
(Table 3). Increasing doses of PCC were associated with sig-
nificantly higher utilization of blood product transfusion, and
this was reflected in the data for individual blood components
(red blood cells, platelets, FFP, and cryoprecipitate). Conse-
quently, treatment cohort patients who received PCC and FFP
with a PCC dose of "20 IU/kg had the lowest reported effec-
tiveness and the highest utilization of blood products (including
red blood cells), indicating combined use of multiple treat-
ments in the management of excessive bleeding. In the prophy-
lactic cohort (patients receiving PCC alone), there was a
nonsignificant trend toward a lower incidence of blood product
transfusion with a PCC dose of "20 IU/kg compared to doses
of 10.0 to 19.9 IU/kg.
Baseline INR values and responses to treatment are shown
in Table 4. Decreases in median values were observed among
recipients of PCC and/or FFP, in both cohorts, between base-
line and 3 hours postdose. Little change was observed between
3 and 24 hours postdose. Where data were available at both
baseline and 3 hours postdose, statistically significant improve-
ments in INR were evident in most of the patient groups.
Safety and Tolerability (Data Collected Only for Patients
Receiving PCC)
The ADRs reported could be broadly categorized either as
ineffective therapy or as thromboembolic events (Table 5).
“Drug ineffective” was reported in 6 treatment cohort patients
(1.6% of all PCC recipients).
Thromboembolic events occurred in 7 (1.9%) PCC recipi-
ents during the 24-hour observation period, and all except 1
were in the treatment cohort. All of these events were arterial
and 1 was associated with patient death (see below). All were
considered by the investigators to be possibly related to PCC
therapy. Additional treatments received by patients with throm-
boembolic events (most commonly platelet concentrate
Table 2. Interventions/Procedures Performed in (A) the Prophylactic and (B) the Treatment Cohort, by Treatment Administered.
(A) Prophylactic Cohort
PCC Alone,
n ¼ 16
PCC and FFP,
n ¼ 5
FFP Alone,
n ¼ 19
All Patients,
n ¼ 40
Intervention/procedure
Minor procedure 8 3 11 22
Lumbar puncture or epidural 3 0 3 6
Central venous lines–placement and removal 0 2 0 2
Arterial access 2 1 0 3
Tracheostomy 0 0 2 2
Liver biopsy 0 0 2 2
Endoscopy with/without endoscopic retrograde cholangiopancreatography (ERCP) 0 0 3 3
Chest drain with pleural aspiration 1 0 0 1
Other (including patients undergoing multiple procedures) 2 0 1 3
Major procedure 8 2 8 18
Abdominal surgery 2 0 5 7
Cranial surgery 5 1 0 6
Major vascular surgery 0 1 2 3
Other 1 0 1 2
(B) Treatment Cohort
Intervention/procedure
PCC Alone,
n ¼ 228
PCC and FFP,
n ¼ 123
FFP Alone,
n ¼ 54
All Patients,
n ¼ 405
Cardiovascular surgery 218 113 51 382
Isolated first-time CABG 60 22 23 105
Isolated aortic valve replacement 30 9 10 49
Mitral valve replacement or repair with/without tricuspid valve replacement 26 13 2 41
Aortic valve replacement with CABG 28 12 8 48
Mitral valve replacement or repair (+ tricuspid valve replacement) with CABG 22 3 2 27
Multiple valve procedure with/without CABG 11 12 1 24
Simple aortic surgery 16 13 2 31
Complex aortic surgery 4 4 0 8
Other complex surgery (including endocarditis and re-do surgery) 21 25 3 49
Gastrointestinal surgery 0 7 2 9
Neurological/nervous system surgery 2 2 0 4
Musculoskeletal surgery 1 0 0 1
Other surgical procedures 7 1 1 9
Abbreviations: CABG, coronary artery bypass graft; FFP, fresh frozen plasma; PCC, prothrombin complex concentrate
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[n ¼ 7], vitamin K [n ¼ 6], desmopressin [n ¼ 6], cryopreci-
pitate [n ¼ 6], and red blood cells [n ¼ 5]) are shown in
Supplementary Table 1.
Twelve deaths occurred among PCC recipients during the
24-hour observation period, and one of these was assessed by
the investigator to have been possibly related to PCC treatment.
The patient, a 70-year-old woman in the prophylactic cohort
with a diagnosis of acute promyelocytic leukemia, was treated
with 2 doses of PCC on consecutive days (1750 IU [27 IU/kg]
and 1000 IU [16 IU/kg]). Two units of platelet concentrate
were also administered. Death occurred on the same day that
the second dose of PCC was given. The cause of death was
reported as “relapsed acute promyelocytic leukemia and acute
myocardial infarction.” The patient was being treated with all-
trans retinoic acid, but her history in relation to ischemic heart
disease is unavailable. Causes of death for the remaining 11
patients were listed as follows: multiorgan failure secondary to
overwhelming sepsis; neutropenic sepsis, multiorgan failure;
end-stage renal disease, diabetes mellitus, multiorgan failure;
advanced lung cancer, low vital capacity; acute hemorrhagic
pancreatitis; multiple organ failure due to sepsis, endocarditis,
and pneumonia; heart failure; ischemic bowel disease, acceler-
ated ventricular rhythm; ruptured hepatic artery aneurysm;
multiorgan failure, tricuspid valve disease, mitral valve dis-
ease, chronic obstructive pulmonary disease; and bowel infarc-
tion, myocardial infarction, renal and hepatic failure, and
ischemic heart disease (operated).
Three additional deaths occurred outside the 24-hour
observational period, all in the treatment cohort patients. All
three patients had a thromboembolic adverse event: 2 cerebral
ischemic events and 1 myocardial infarction. The lengths of
time between study drug administration and death were
4 days, 114 days, and 188 days. One of these deaths (the
patient with myocardial infarction who died 4 days after PCC
therapy) was considered by the investigator to be possibly
related to study drug.
Discussion
To date, this is the largest retrospective study on the clinical use
of PCCs for acquired coagulopathy and/or perioperative bleed-
ing in routine practice. The results show that PCC was used
across a variety of clinical settings with wide dose ranges. Its
clinical effectiveness was judged as very good or satisfactory in
93.0% of patients receiving PCC alone (87.5% in the prophy-
lactic cohort and 93.4% in the treatment cohort). The corre-
sponding effectiveness rate among patients receiving FFP only
was 86.3%, but this result cannot be used for comparison. The
PCC produced statistically significant reductions in INR. For
example, 3 hours after PCC infusion in the prophylactic cohort
(PCC alone group), the mean INR was <1.5. The incidence of
thromboembolic events with PCC was lower than in the pub-
lished literature for the cohort under treatment.25-28
Around 90% of patients received only 1 dose of PCC. In
the treatment cohort, there was potential to titrate the dose
upward if required, while the intention in the prophylactic
cohort was to administer a single, effective dose. In the treat-
ment cohort, a wide range of PCC doses were used with no
apparent association between dose and effectiveness with
PCC alone. However, in the PCC and FFP group, PCC dose
and effectiveness were inversely related. Patients receiving
the highest PCC doses ("20 IU/kg) had the highest utilization
of blood products, suggesting selection bias toward more
severely bleeding patients.
Published studies on the use of PCC for bleeding unrelated to
oral anticoagulation in nonspecific or cardiac surgery settings
Figure 1. Effectiveness in (A) the prophylactic cohort and (B) the treatment cohort. Effectiveness was judged by the physician as very good,
satisfactory, questionable/doubtful, none, or no judgment possible with regard to preventing bleeding (prophylactic cohort) or stopping
bleeding (treatment cohort). FFP indicates fresh frozen plasma; PCC, prothrombin complex concentrate.
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are limited. In a small study of 16 patients with bleeding related
to cardiac and noncardiac surgery, despite near-normal coagula-
tion tests, PCC administration (average dose <1500 IU) was
associated with partial or complete hemostasis in 75% of the
patients.14 A retrospective study of 38 noncardiac surgery
patients with severe perioperative bleeding reported that PCC
(median dose 2000 IU) stopped bleeding in 96% of patients with
microvascular bleeding and 36% of patients with surgical bleed-
ing within 3 hours of administration.16 In another retrospective
study in bleeding related to cardiopulmonary bypass, low-dose
PCC (10-14 IU/kg) was associatedwith decreased postoperative
bleeding.13 Similarly, 2000 IU PCC normalized PT and stopped
bleeding in all 16 patients in a study of acquired coagulopathy in
critical care.29 The doses of PCC in the present study are similar
to or lower than those of the previous studies but lower than
those used for reversal of oral anticoagulation (typically 25-50
IU/kg, depending on baseline INR23,30).
In our study, bleeding after cardiac surgery was the domi-
nant setting for PCC use. Around 6% of patients bleed exces-
sively after cardiac surgery, and this is a major cause of
mortality and morbidity.31 Studies in patients with excessive
blood loss after cardiac surgery have shown a variety of
coagulation-related deficiencies including low platelet
counts, low levels of coagulation factors IX, X, XI, and low
endogenous thrombin potential.32-34 Thus, bleeding is multi-
factorial in nature, and a range of different hemostatic treat-
ments may be needed.18,34,35 This is reflected in the current
study where 60% of patients treated for perioperative bleeding
received platelet concentrate, 46% received red blood cells,
and 25% received cryoprecipitate, in addition to PCC and/or
FFP. The PCC has been investigated within treatment algo-
rithms as a second-line treatment for perioperative bleeding
following fibrinogen supplementation.35-37
Based on published concentrations of coagulation factors
within Beriplex P/N and FFP,38 the median PCC dose in this
study resulted in the administration of more than 50% higher
quantities of FII, FIX, and FX compared to the median dose of
FFP.9,39 Several in vitro studies have demonstrated the influ-
ence of prothrombin and antithrombin levels on thrombin gen-
eration, with increasing levels of the former and decreasing
Table 4. International Normalized Ratio (INR) Results.
All Available Dataa
3 Hours Postdose vs Baseline–Data
Only for Patients With Values at Both
Time Points
Patients Baseline 3 Hours Postdose 24 Hours Postdose Change, Median (95% CI) P Value
INR: Prophylactic cohort
Patients receiving PCC alone
(n ¼ 16)
1.7 (1.5-1.9), n ¼ 14 1.4 (1.2-1.5), n ¼ 10 1.5 (1.4-1.6), n ¼ 11 $.3 ($.4 to $0.1) n ¼ 10 .005
Patients receiving PCC & FFP
(n ¼ 5)
2.1 (1.8-3.0), n ¼ 5 1.8 (1.6-2.4), n ¼ 5 1.9 (1.6-2.2), n ¼ 5 $.4 ($.8 to 0), n ¼ 5 .06
Patients receiving FFP alone
(n ¼ 19)
1.7 (1.6-1.9), n ¼ 13 1.4 (1.3-1.5), n ¼ 15 1.4 (1.3-1.5), n ¼ 11 $.3 ($.6 to $.2), n ¼ 13 .001
INR: Treatment cohort
Patients receiving PCC alone
(n ¼ 228)
1.5 (1.3-1.7), n ¼ 131 1.2 (1.2-1.2), n ¼ 176 1.2 (1.1-1.3), n ¼ 124 $.3 ($.4 to$.2), n ¼ 96 <.001
Patients receiving PCC & FFP
(n ¼ 123)
1.6 (1.4-1.9) n ¼ 62 1.2 (1.1-1.4), n ¼ 90 1.2 (1.1-1.4) , n ¼ 39 $.4 ($.5 to $.3), n ¼ 49 <.001
Patients receiving FFP alone
(n ¼ 54)
1.4 (1.2–1.6), n ¼ 27 1.2 (1.1-1.3), n ¼ 36 1.2 (1.0-1.2), n ¼ 40 $.3 ($.5 to .1), n ¼ 14 .002
Abbreviations: CI, confidence interval; FFP, fresh frozen plasma; PCC, prothrombin complex concentrate.
aData shown are median (interquartile range).
Table 5. Safety Outcomes Among all Recipients of Prothrombin
Complex Concentrate (PCC): Numbers of Affected Patients (%).
Event
Prophylactic
Cohort
(n ¼ 21)
Treatment
Cohort
(n ¼ 347)
Both Cohorts
Combined
(n ¼ 368)
Any adverse drug reactiona 1 (4.8)b 6 (1.7)c 7 (1.9)
Drug ineffective 0 (0.0) 6 (1.7) 6 (1.6)
Hemorrhage 0 (0.0) 3 (.9) 3 (.8)
Thromboembolic event 1 (4.8) 6 (1.7) 7 (1.9)d
Cerebral ischemic event 0 (0.0) 5 (1.4) 5 (1.4)
Myocardial infarction 1 (4.8) 1 (.3) 2 (.5)
Death 3 (14.3) 9 (2.6) 12 (3.3)
aExcluding thromboembolic events and deaths.
bOne patient had relapsed acute promyelocytic leukemia and acute myocardial
infarction
cDetails of the adverse drug reactions in these 6 patients are as follows: “drug
ineffective” (3 patients); “drug ineffective” and hemorrhage (2 patients); and
atrial fibrillation, atrial flutter, cerebral infarction, cerebrovascular accident,
delayed recovery from anesthesia, disturbance in attention, “drug ineffective,”
hemorrhage, hemiparesis, mechanical ventilation, nervous system disorder,
pericardial hemorrhage, retinal artery embolism, tracheostomy, unresponsive
to stimuli, ventricular arrhythmia, vision blurred, and visual acuity reduced
(1 patient)
dAdditional treatment was administered to these patients as follows: platelet
concentrate (n ¼ 7), vitamin K (n ¼ 6), desmopressin (n ¼ 6), cryoprecipitate
(n ¼ 6), red blood cells (n ¼ 5) and fibrinogen (n ¼ 1; see Supplementary
Table 1).
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levels of the latter associated with higher thrombin genera-
tion.40-42 Ex vivo spiking studies of plasma samples taken after
cardiopulmonary bypass surgery have shown restoration of
thrombin generation with PCCs.43,44
The potential for thrombogenicity is a key safety consider-
ation when administering PCC.45,46 A recent pharmacovigi-
lance study of Beriplex P/N, covering 647,250 applications
over a 16-year period (mainly for reversal of vitamin K antago-
nists), reported that the incidence of thromboembolic events is
*1:31,000 treatments.47 In this context, patients’ underlying
conditions and the administration of other treatment inevitably
affect the risk of thromboembolic adverse events. Reported
incidences of deep vein thrombosis after cardiac surgery are
as high as 15% to 46%, while pulmonary embolism occurs in
0.3% to 9.5% of patients.28,48 For CABG, 1% to 5% of patients
are affected by stroke, and myocardial infarction has been
reported to occur in 4% to 8% of patients.25,26 These percen-
tages are higher than the 1.9% of PCC recipients in this study in
whom thromboembolic events were reported, but we collected
data only for the first 24 hours posttreatment, and this was a
limitation of the study. Overall, in the present study, there were
multiple risk factors for thromboembolic complications aside
from the use of PCC.
This study has several additional limitations, including its
retrospective nature, variations between centers in routine
clinical practice, and the subjective method of assessing
effectiveness. The criteria for administration of PCC and FFP
(particularly in the prophylactic cohort) were related to prac-
tices of the individual clinicians and institutes included in the
study; variability in this respect is reflected by the fact that 41%
of the patients had no documented evidence of hemostatic
impairment. Inappropriate use of FFP in surgery/trauma is
well-documented, and the present study may have included
patients not requiring hemostatic intervention.49 Furthermore,
the use of tranexamic acid in the patients undergoing cardio-
vascular surgery was limited; strong evidence supporting the
use of this drug has emerged since the study was performed.50
The retrospective nature of the study and the method for asses-
sing effectiveness introduced potential for bias. However, the
observation of similar effectiveness rates with either FFP or
PCC could be interpreted as suggesting a similar impact of bias
with both treatments. The study was not designed to compare
the effectiveness of PCC versus FFP despite the inclusion of
patients receiving both of these treatments. Numbers of
patients receiving FFP alone and PCC alone were not balanced,
and ratios of patient numbers across the study groups do not
reflect those of clinical practice. Also, the safety analysis was
limited by the collection of data only for patients who received
PCC and only for a short period of time (24 hours) and by the
lack of collection of safety data for FFP.
Conclusions
In conclusion, these real-life data show that PCC can be effec-
tive in perioperative and intensive care as a single agent and as
part of multifaceted hemostatic intervention in the management
of perioperative bleeding. One advantage of using coagulation
factor concentrates as opposed to allogeneic blood products is
that they can be prepared and administered more quickly. Fur-
ther studies with defined indications and more objective criteria
for efficacy assessment are needed to ascertain the role of PCC
in the management of perioperative bleeding.
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